https://doi.org/10.4081/reumatismo.2016.911

Aseptic HLA B27-positive spondylodiscitis: decreased 18F-FDG uptake after etanercept treatment

Vol. 68 No. 3 (2016)
Submitted: 17 July 2016
Accepted: 11 October 2016
Published: 16 December 2016
Spondylodiscitis, etanercept, ankylosing spondylitis.
Abstract Views: 3022
PDF: 773
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

M. Benucci
maurizio.benucci@uslcentro.toscana.it
Rheumatology Unit, S. Giovanni di Dio Hospital, Firenze, Italy.
A. Damiani
Rheumatology Unit, S. Giovanni di Dio Hospital, Firenze, Italy.
A. Arena
Nuclear Medicine Unit, New Hospital, Prato, Italy.
M. Infantino
Immunology and Allergology Laboratory Unit, S. Giovanni di Dio Hospital, Firenze, Italy.
M. Manfredi
Immunology and Allergology Laboratory Unit, S. Giovanni di Dio Hospital, Firenze, Italy.
F. Li Gobbi
Rheumatology Unit, S. Giovanni di Dio Hospital, Firenze, Italy.
We observed a 69-year old man suffering from HLA B27 ankylosing spondylitis with persistent night back pain. 18F-FDG-PET/CT showed an increased metabolism at the level of the spinal space of L2-L3, L3-L4 with increased uptake compatible with spondylodiscitis. He started therapy with etanercept 50 mg/week. After six months of treatment repeated testing showed no uptake of the discs and vertebral bodies.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
M. Benucci, Rheumatology Unit, S. Giovanni di Dio Hospital, Firenze
Internal Medicine

How to Cite

Benucci, M., Damiani, A., Arena, A., Infantino, M., Manfredi, M., & Li Gobbi, F. (2016). Aseptic HLA B27-positive spondylodiscitis: decreased 18F-FDG uptake after etanercept treatment. Reumatismo, 68(3), 163–165. https://doi.org/10.4081/reumatismo.2016.911

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.